Standard Treatment Guidelines for Common Illness of Adults in Papua New Guinea

Objectives

The Adult Standard Treatment Manual provides standardised, safe, appropriate and cost-effective guidance for managing common adult illnesses in Papua New Guinea. It is intended for nurses, Health Extension Officers and doctors, and aims to support care that addresses patients’ needs and rights, medicine side effects, and possible procedural complications.[1]It functions as a national clinical reference rather than a broader health-sector strategy, bringing together guidance across emergency, infectious, non-communicable, mental health, respiratory, skin, neurological, eye, gastrointestinal, cardiovascular and musculoskeletal conditions.[2][3]

• Standardise diagnosis, treatment, follow-up, referral and patient education across health-service levels through a common adult clinical manual.[1][4]
• Update treatment strategies in response to changing disease patterns and antimicrobial resistance, drawing on local resistance data from the National Department of Health and the Papua New Guinea Institute of Medical Research.[5]
• Incorporate disease-specific recommendations for malaria, tuberculosis, HIV/AIDS and diabetes, alongside detailed guidance for other priority clinical conditions.[5][6][7]
• Expand clinical coverage through chapters on obesity, cholera, influenza-like illness and scabies, plus annexes on laboratory reference values and malaria rapid diagnostic testing.[5]
• Promote prevention and self-management where relevant, including lifestyle modification for diabetes, hypertension and obesity; transmission prevention for HIV/AIDS and cholera; household treatment for scabies; and patient and family education for tuberculosis and leprosy.[8][9][10][7][4][11]
• Support disease-control objectives in specified programmes, including tuberculosis cure rates above 85% among new positive cases and case detection above 70% of estimated new positive cases, as well as continued surveillance to maintain polio-free status.[12][13]

Implementation

The manual is designed for routine use across Papua New Guinea health services, except where professional judgement supports an alternative course of action.[1]It links clinical guidance to health-worker training, national service standards and medicine supply arrangements, and serves alongside separate standard treatment manuals for paediatrics, obstetrics and gynaecology, and surgery.[1]Delivery is primarily facility-based and combines assessment, testing where available, first-line treatment, clinical observation, referral and transfer for severe, uncertain or treatment-resistant cases.[14][15]

• Align practice with National Health Service Standards, the Papua New Guinea National Formulary, the National Essential Medicine List, and more detailed disease-specific guidance where required.[1][5]
• Apply revised first-line and second-line regimens, including fixed-dose combinations for malaria, tuberculosis and HIV/AIDS, in response to resistance patterns and national protocols.[5]
• Use structured clinical assessment and available investigations, such as malaria microscopy or rapid diagnostic tests, blood testing, imaging, microbiology, lumbar puncture and sputum examination, to identify causes and guide treatment or escalation.[16][17][18]
• Provide emergency stabilisation for acute illness through airway management, oxygen, intravenous fluids, analgesia, antimicrobial treatment where indicated, observation and referral.[19][20]
• Escalate care through defined referral criteria for serious conditions, treatment failure, diagnostic uncertainty, suspected complications, specialist treatment needs or unavailable resources, while maintaining appropriate care during transfer.[21][22][23]
• Deliver tuberculosis control through the Directly Observed Treatment Short-course strategy, including political and community support, sputum microscopy to identify infectious cases, directly observed first-line treatment, reliable medicine supplies, patient registration and treatment records.[12][4]
• Strengthen adherence by supervising tuberculosis and leprosy treatment, educating patients and families, recording doses, tracing people who miss treatment, and managing interruptions through defined pathways.[4][24][11]
• Integrate diabetes care into the wider health system where dedicated diabetes clinics are unavailable, using trained staff and protocols, education, dietary change, physical activity, weight management, medicines and referral for intensive management.[6][25][9]
• Coordinate technical development through the National Department of Health, the Society of Physicians, clinical discipline leaders, local and international experts, the Papua New Guinea Institute of Medical Research and the World Health Organization.[1][5]
• Use targeted reporting and disease-control links where specified, including notification of unusually large diarrhoea or dysentery clusters to the Provincial Health Adviser, confirmed typhoid to the provincial disease control officer, yaws to the Provincial Disease Control Officer, and acute floppy paralysis to public-health authorities.[10][26][27][28]

Monitoring is mainly clinical and condition-specific, including treatment review, vital-sign observation, diagnostic reassessment, fluid-balance monitoring and follow-up testing.[15][22][25]The tuberculosis programme additionally uses an information system to record, monitor, report and evaluate control activities, supported by treatment cards, registration records and sputum follow-up.[12][4]Apart from these specified arrangements, the material does not set out a single document-wide monitoring framework, reporting schedule, evaluation plan or accountability system.[1][29]

No overall implementation budget, quantified costing, financing allocation or funding gap is specified.[1][30]The World Health Organization provided editorial assistance and funding for development of the manual, although no amount or financing terms are given.[1][5]Adequate funding and reliable medicine supply are identified as necessary for effective tuberculosis control, while the wider manual presents cost-effective management as an intended benefit rather than a costed programme outcome.[12][1]

Monitoring & Evaluation

The manual has limited programme-level monitoring arrangements in the supplied material, but establishes clinical monitoring, follow-up, referral, disease notification and record-keeping requirements across conditions. Local antimicrobial-resistance data from the National Department of Health and Papua New Guinea Institute of Medical Research are intended to inform revision of treatment strategies.[5]The tuberculosis control programme is the clearest exception, using a formal information system to record, monitor, report and evaluate performance.[12]

• Track tuberculosis outcomes against targets of a cure rate above 85% among new positive cases and case detection above 70% of estimated new positive cases.[12]
• Register tuberculosis patients through treatment and personal cards and the tuberculosis registration book, record every supervised dose, and obtain follow-up sputum at two, four and six months.[4]
• Use sputum culture and drug-susceptibility testing when sputum remains positive at two months or when treatment interruption requires further assessment.[4][24]
• Monitor leprosy treatment with skin smears every six months, adverse-effect checks, treatment-completion periods and referral where smears remain positive after 24 months.[11]
• Notify unusually high numbers of diarrhoea or dysentery cases to the Provincial Health Adviser, confirmed typhoid cases to the provincial disease control officer, and suspected yaws to the Provincial Disease Control Officer.[10][26][28]
• Maintain surveillance for acute floppy paralysis to support Papua New Guinea’s polio-free status, including immediate referral of suspected poliomyelitis and notification of acute floppy paralysis.[13][27]
• Use malaria blood slides or rapid diagnostic tests to guide treatment, repeat microscopy when second-line treatment is considered, and confirm failure within 14 days by microscopy.[17]
• Assess and escalate severe malaria according to clinical severity indicators and response to artesunate, referring patients who do not improve after 24 hours.[31][23]
• Observe poisoning cases for 24 hours, monitor snakebite patients for envenoming and retain them in a health facility or hospital for at least three days.[19][32]
• Monitor serious burns through pulse, blood pressure and urine output every 30 minutes during transfer preparation, and use urine output to guide fluid replacement.[21]
• Review diabetes control after treatment changes, record weight-management goals and progress, and monitor body mass index, waist circumference, diet and physical activity.[25][9]
• Assess hypertension on repeated blood-pressure measurements and review patients receiving antihypertensive medicines regularly.[33]
• Reassess selected clinical conditions at defined intervals, including chronic otitis media every two weeks, arthritis after 48 hours, pneumonia after two days or 24 hours in severe illness, and corneal ulcers daily until staining clears.[6][34][35][36]

Most other sections do not specify routine programme indicators, reporting schedules, surveillance architecture, formal evaluation methods or institutional accountability mechanisms beyond condition-specific clinical observation, referral, testing and treatment records.[2][37][16][38][29]

Costing & Financing

The supplied material provides almost no quantified costing, budget allocation, financing plan, funding-gap analysis or economic assumption for implementing the adult standard treatment guidance.[1][5]The World Health Organization provided editorial assistance and funding for development of the manual, but neither the amount nor the funding terms are specified.[1][5]Safe, appropriate and cost-effective patient management is identified as an intended benefit rather than a quantified economic outcome.[1]

• Identify adequate funding as a critical input for the Directly Observed Treatment Short-course tuberculosis strategy, together with political and community support and reliable supplies of tuberculosis medicines.[12]
• Link medicine availability to the Papua New Guinea National Formulary and National Essential Medicine List, without specifying procurement budgets or financing arrangements.[5]
• Recognise that the guidance identifies clinical resource needs, including medicines, diagnostics, oxygen, intravenous fluids, blood transfusion, referral, treatment cards and laboratory testing, but does not assign financial values to these inputs.[39][40][4]
• Describe dietary change and increased physical activity as the most economical means of weight loss, while noting that nutritionist support depends on availability.[9]

No monetary allocations, resource-mobilisation mechanisms, funding sources beyond the unspecified World Health Organization contribution, or explicit funding gaps are provided in the supplied material.[1][12][29]